anti-Phospholamban Phospho Threonine-17 anti-serum （A010-13）

详细介绍

产品咨询

Badrilla，Badrilla代理，Badrilla北京代理，Badrilla国内代理，Badrilla代理，Badrilla一级代理，Badrilla中国代理

badrilla 生物技术公司成立于2003年，总部位于利英国。badrilla使分配特殊的单克隆抗体和多克隆抗体的蛋白质和磷酸化蛋白的目标心血管。 badrilla生命科学试剂公司专注于研究工具为心血管疾病的研究，尤其是对心肌兴奋收缩偶联。badrilla为工业界和学术界的研究实验室制造 和验证抗体的心脏蛋白和磷酸蛋白。

上海金畔生物科技有限公司badrilla专业代理，具体产品信息欢迎电询：

anti-Phospholamban Phospho Threonine-17 anti-serum (A010-13)

Description: A fully validated, highly specific rabbit polyclonal anti-sera to Threonine-17 phosphorylated forms of Phospholamban (anti-PLB PT-17)

Background: Phospholamban (PLB/PLN) is a small transmembrane protein which plays an important role in controlling the activity of the sarcoplasmic reticulum ATPase (SERCA2a) of cardiac muscle during calcium sequestration. Phospholamban is phosphorylated on separate amino acid residues by cAMP-dependent, and cGMP-dependent (Ser-16) and Ca²⁺/CaM-dependent (Thr-17) protein kinases in response to β-adrenergic stimulation. Akt has also been shown to phosphorylate Thr-17. The result is an increased calcium pump activity which reduces the time course of the calcium transient, increases the calcium load in the sarcoplasmic reticulum, and consequently, produces a larger calcium transient at the next action potential. However, alteration in this homeostatic interaction has been shown to result in heart failure.

Unit Volume: 20 ul

Tested Applications: Western Blot (1:5000 dilution), IHC Microscopy (1:200 dilution)

Antibody form: Lyophilised anti-serum

Species recognition: All mammalian species, when phosphorylated on Thr-17

Full Publication list: 111 papers

上海金畔生物科技有限公司